TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11202321
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment
Study: 8517512
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 25 ml
Study: 8517512
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg in normal saline 25 ml
Study: 8517512
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupivacaine 0.5% 12.5 ml and 5 mg of morphine in normal saline 25 ml
Study: 8517512
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 25 ml
Study: 3031840
Drug: Misonidazole 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole 1.2 g/m2 orally on treatment day
Study: 29151116
Drug: No alpha-1
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alpha-1 blocker (Group 1)
Study: 24886179
Drug: Internet-delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Cognitive Behavior Therapy (iCBT) program consisting of 8 weekly modules with post-session feedback support.
Study: 24886179
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control group receiving access to the treatment at week 8.
Study: 18602724
Drug: 11-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-valent pneumococcal protein D (PD)-conjugate study vaccine
Study: 18602724
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (HAV) (control)
Study: 18602724
Drug: 11-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-valent pneumococcal PD-conjugate study vaccine
Study: 15629356
Drug: Hexavalent DTPa-HBV-IPV/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent DTPa-HBV-IPV/Hib vaccine
Study: 12271279
Drug: Postoperative imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Postoperative imiquimod 5% cream applied for 8 weeks
Study: 12271279
Drug: Postoperative imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Postoperative imiquimod 5% cream
Study: 415643
Drug: Gold salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold salt treatment
Study: 21944654
Drug: Eurythmy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurythmy therapy (EYT)
Study: 30856689
Drug: Zolpidem 5
Normalized name: zolpidem 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 5 mg daily for 4 weeks
Study: 15564167
Drug: piperacillin/tazobactam 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin/tazobactam 4 g/500 mg every 8 hours
Study: 15564167
Drug: imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipenem/cilastatin 500 mg/500 mg every 6 hours
Study: 11745931
Drug: Interferon-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (3 MU three times weekly for 52 weeks)
Study: 3499066
Drug: Pyridoxine HCl
Normalized name: PYRIDOXINE HCL
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine HCl 50 mg/d
Study: 22631063
Drug: 24‐hour steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24‐hour steroid avoidance group (n=41)
Study: 16985020
Drug: TSER, TSER
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSER, TSER 3R G>C, and TS 1494del6 variants
Study: 12838195
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine supplementation (0.3 g/kg/day)
Study: 29956215
Drug: Co-Crystal of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-Crystal of Tramadol-Celecoxib (CTC) 100 mg, 150 mg, and 200 mg administered orally
Study: 25209520
Drug: Ozenoxacin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozenoxacin 2% cream applied once daily (0.2 g per application)
Study: 25209520
Drug: Ozenoxacin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozenoxacin 2% cream applied twice daily (0.2 g per application, 12 h apart)
Study: 19129749
Drug: Dapagliflozin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 100 mg
Study: 19129749
Drug: Dapagliflozin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 25 mg
Study: 22776824
Drug: Dapagliflozin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (all doses)
Study: 11601838
Drug: Trapidil 200
Normalized name: trapidil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil 200 mg
Study: 9586849
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Zolpidem (Zol)
Study: 9586849
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Diazepam (Dz)
Study: 9586849
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Oxazepam (Ox)
Study: 9586849
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg Zopiclone (Zop)
Study: 9586849
Drug: Ethanol (EOH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (EOH; 0.65 + 0.35 g x kg(‐1))
Study: 7989704
Drug: Ribavirin (800,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (800, 1000, or 1200 mg/kg per day)
Study: 2499922
Drug: Rioprostil 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rioprostil 100 micrograms twice daily
Study: 26353424
Drug: 1 500
Normalized name: vit-B1 500 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 500 ml of Ringers lactate
Study: 26353424
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of 6% pentastarch
Study: 26353424
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 250 ml of 6% pentastarch and 750 ml of Ringers lactate
Study: 23291800
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg olanzapine daily for 8 weeks
Study: 23291800
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg risperidone daily for 8 weeks
Study: 8986916
Drug: Quinapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20 mg single dose)
Study: 3904382
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase (SK) therapy
Study: 31054568
Drug: LIDO (lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIDO (lidocaine 1.5 mg/kg loading, 1.5 mg/kg/h infusion)
Study: 31054568
Drug: DEX (dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (dexmedetomidine 0.5 μg/kg loading, 0.4 μg/kg/h infusion)
Study: 30107054
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (e.g., fluoroquinolones)
Study: 26778006
Drug: Long-term androgen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term androgen deprivation therapy (ADT) (≥ 2 years)
Study: 26778006
Drug: Short-term androgen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term androgen deprivation therapy (ADT) (< 2 years)
Study: 24240712
Drug: Prehospital cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital cooling (infusion of up to 2 L of 4°C normal saline)
Study: 18684310
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX)‐A injections into the upper limb
Study: 1964751
Drug: Fragmin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin (low molecular weight heparin) subcutaneously (120 anti-FXa U/kg) twice daily
Study: 1964751
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (SH) as continuous intravenous infusion (480 IU kg‐1 day‐1)
Study: 2834482
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (SH)
Study: 1964751
Drug: Fragmin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin and Standard heparin (SH)
Study: 29040012
Drug: ALLIC 2002
Normalized name: gallic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLIC 2002 protocol treatment for patients with Down syndrome
Study: 29040012
Drug: ALLIC 2002
Normalized name: gallic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLIC 2002 protocol treatment for patients without Down syndrome
Study: 18503774
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day for the first month and 8 mg/day thereafter; n = 32)
Study: 12841927
Drug: Etodolac SR
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac SR (400 mg/day)
Study: 27470088
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 mg/day)
Study: 10885603
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (methotrexate 100 mg/m2 and cisplatin 50 mg/m2 for 3 cycles at 2-week intervals)
Study: 1408479
Drug: High titer
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titer Edmonston-Zagreb vaccine at 5 to 6 months of age
Study: 1408479
Drug: Standard titer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard titer Schwarz vaccine at 8 to 9 months of age
Study: 1408479
Drug: High titer
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titer Biken-CAM vaccine at 8 to 9 months of age
Study: 4062396
Drug: Empirical antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antibiotic therapy (trimethoprim-sulfamethoxazole and erythromycin)
Study: 27729174
Drug: Vaccine stored
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine stored at elevated temperatures (25 °C for up to six months or 30 °C for three months)
Study: 27729174
Drug: Cold-chain stored
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-chain stored vaccine (2–8 °C)
Study: 16048260
Drug: NEPP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPP (1 dwell amino acids, 1 dwell icodextrin, and two dwells bicarbonate/lactate-buffered glucose-based solution)
Study: 10500056
Drug: Infliximab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (10 mg/kg every 8 weeks)
Study: 8744663
Drug: Intravenous nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalbuphine infusion (15 micrograms/kg/h)
Study: 2531153
Drug: Nafarelin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin (400 micrograms daily)
Study: 2531153
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg daily)
Study: 17463418
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 2.5 mg vitamin D
Study: 11591229
Drug: Water-miscible retinyl
Normalized name: RETINYL PALMITATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-miscible retinyl palmitate (112 mg)
Study: 11591229
Drug: Oil-soluble retinyl
Normalized name: RETINYL PALMITATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-soluble retinyl palmitate (112 mg)
Study: 11271260
Drug: Ganciclovir (DHPG)
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir (DHPG) 3 mg/kg q 12 h for 2 weeks, plus CMV-hyperimmunglobulin (1 ml/kg per week for 6 weeks) if CMV+ donor
Study: 3122967
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg in the morning
Study: 28110919
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (Xylocaine gauze applied for 2 minutes)
Study: 25673087
Drug: LB30870 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB30870 60 mg
Study: 25673087
Drug: LB30870 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB30870 120 mg
Study: 25673087
Drug: LB30870 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB30870 (various doses)
Study: 25673087
Drug: LB30870 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB30870 (doses above 15 mg)
Study: 25673087
Drug: LB30870 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB30870 (60 mg)
Study: 25673087
Drug: LB30870 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB30870 (up to 240 mg)
Study: 24284841
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (40 mg and 20 mg)
Study: 18444815
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of metronidazole under directly observed therapy
Study: 16472979
Drug: 6% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate (CHO) solution
Study: 16472979
Drug: 6-g essential
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-g essential amino acid (EAA) mixture
Study: 16472979
Drug: Combined CHO+EAA
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CHO+EAA supplement
Study: 14512130
Drug: 2 loratadine
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 loratadine 5‐mg tablets + ambroxol 30‐mg tablets (Formulation A)
Study: 14512130
Drug: 1 loratadine
Normalized name: loratadine 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 loratadine 10‐mg tablet (Formulation C)
Study: 14512130
Drug: 2 ambroxol
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ambroxol 30‐mg tablets (Formulation B)
Study: 7924865
Drug: Preoperative parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative parenteral nutritional support (PNS) for 5 days, yielding 117 Kj.kg‐1.d‐1 of non‐protein calories and 0.15g.kg‐1.d‐1 of nitrogen.
Study: 7924865
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with 5‐Fu at 8‐10mg.kg‐1.d‐1 for 5 days and mitomycin C at 6‐8mg.d‐1 on the first and fifth day.
Study: 7924865
Drug: PNS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNS plus chemotherapy (5‐Fu and mitomycin C) as in Groups A and B.
Study: 29132880
Drug: Rivaroxaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (5 mg twice a day)
Study: 29132880
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg once a day)
Study: 30488637
Drug: Antipsychotic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic dose reduction strategy with evidence-based intensive recovery treatment (DRS+)
Study: 30488637
Drug: Antipsychotic maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic maintenance treatment with evidence-based intensive recovery treatment (AMTx+)
Study: 30488637
Drug: Antipsychotic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic dose reduction strategy (DRS+)
Study: 30488637
Drug: Antipsychotic maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic maintenance treatment (AMTx+)
Study: 9147610
Drug: Idarubicin (Ida)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (Ida) 10 mg/m2 given as a 3 min infusion
Study: 9147610
Drug: Idarubicin (Ida)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (Ida) 10 mg/m2 given as a 2 h infusion
Study: 9147610
Drug: Idarubicin (Ida)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (Ida) in combination with Cytosine arabinoside (Ara‐C, 1 g/m2)
Study: 9147610
Drug: Idarubicin (Ida)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (Ida) as prolonged infusion
Study: 8345007
Drug: Single 300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300-mg dose of phenytoin at 08.00 hours
Study: 8345007
Drug: Single 300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300-mg dose of phenytoin at 20.00 hours
Study: 23471268
Drug: GSK249320 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK249320 (1, 5, or 15 mg/kg per infusion)
Study: 10752681
Drug: Prolonged tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged tamoxifen therapy
Study: 8855856
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate (650 mg twice daily)
Study: 6828092
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg intravenously initially, then 200 mg daily for three months)
Study: 25695295
Drug: Inhaled colistin/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled colistin/oral ciprofloxacin
Study: 25695295
Drug: Nebulized tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nebulized tobramycin 300 mg/oral ciprofloxacin
Study: 22110163
Drug: AM211 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM211 200 mg once daily for 7 days
Study: 22110163
Drug: AM211 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM211 (various doses 100 to 600 mg)
Study: 22110163
Drug: AM211 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM211 (multiple dosing)
Study: 22110163
Drug: AM211 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM211 (all doses)
Study: 20889993
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban (25 μg/kg) in addition to acetylsalicylic acid, unfractionated heparin, and 600 mg clopidogrel.
Study: 20889993
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to acetylsalicylic acid, unfractionated heparin, and 600 mg clopidogrel.
Study: 20889993
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban (25 μg/kg).
Study: 11665396
Drug: 0.3% Flurbiprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% Flurbiprofen gel
Study: 11665396
Drug: 0.3% Triclosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% Triclosan gel
Study: 7991885
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 micrograms via metered dose inhaler, twice daily for 2 weeks)
Study: 7991885
Drug: Theophylline (individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (individually dose‐titrated, twice daily for 2 weeks)
Study: 2643845
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 to 160 mg daily)
Study: 2643845
Drug: Verapamil (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (320 mg daily)
Study: 20109380
Drug: Idrastin lymph‐draining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrastin lymph‐draining cream with elastocompressive therapy
Study: 20109380
Drug: Elastocompressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastocompressive therapy only
Study: 10809036
Drug: Orlistat, 120
Normalized name: Orlistat, 120 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat, 120 mg 3 times a day for 104 weeks
Study: 8614396
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CT) with lomustine (CCNU), vincristine, and prednisone for 1 year
Study: 1600529
Drug: Propafenone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone at 300 mg twice daily
Study: 1600529
Drug: Hydroquinidine retard
Normalized name: Hydroquinidine
DrugBank: Hydroquinidine (DB15300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinidine retard 250 mg twice daily
Study: 3904258
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms ml‐1 hepatitis B vaccine
Study: 3904258
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms ml‐1 hepatitis B vaccine
Study: 29958034
Drug: Multi-ingredient detoxification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient detoxification supplement (1,350 mg/serving)
Study: 23400916
Drug: 5-minute infusion
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-minute infusion of ertapenem 1 g
Study: 23400916
Drug: 30-minute infusion
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute infusion of ertapenem 1 g
Study: 19837318
Drug: PES split
Normalized name: Ipomoea pes-caprae flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PES split crest implants
Study: 19837318
Drug: unsplit alveolar
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unsplit alveolar ridge implants
Study: 17023212
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=12), receiving no treatment
Study: 7719108
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of hyoscyamus, self made Retarded Recovery Pill and acupuncture
Study: 7719108
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of traditional Chinese and Western medicine
Study: 2643074
Drug: Dexamethasone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (3 tablets of 4 mg each)
Study: 2643074
Drug: Dextrose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose placebo (identical in appearance, same dosage schedule)
Study: 31405866
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g) plus piperaquine (960 mg) for three days
Study: 31405866
Drug: Sulfadoxine-pyrimethamine (4,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (4,500 mg sulfadoxine plus 225 mg pyrimethamine, single dose)
Study: 29017627
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g milk protein (MLK20)
Study: 29017627
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g mycoprotein (MYC20)